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Background
Major investments in basic science have created an oppor-
tunity for significant progress in clinical medicine. Mole-
cularly targeted therapies aim to interfere with molecular
mechanisms, selectively involved in carcinogenesis and
tumor growth in order to optimize the efficacy and mini-
mize the side effects of anticancer treatment. Moving from
concept to clinical use requires basic, translational, and
regulatory science. Today, about 10% of labels for FDA-
approved drugs contain pharmacogenomic information—
a substantial increase since the 1990s but hardly the limit
of the possibilities for this aspect of personalized medicine.
Materials and methods
There has been an explosion in the number of promising
markers but significant gap exists in independent analysis
of the validity of the tests used to identify them in biologic
specimens. The success of personalized medicine depends
on having accurate diagnostic tests that identify patients
who can benefit from targeted therapies.
Results
In this presentation, case examples of how MedImmune/
Astrazeneca incorporate personalized medicine/molecular
diagnostic into clinical development to ensure targeted
therapeutics successfully reach the right patient population
will be discussed. These examples will illustrate how close
cooperation among basic science, translational, clinical
and regulatory departments together with partnerships
with diagnostic companies are needed to reduce the
dream of personalized healthcare into practice.
Conclusions
By identifying the right patient population at the outset
of the clinical development process we hope to improve
the probability of success of oncology clinical trials,
which is an urgent requirement across the industry, but
especially for cancer patients with significant unmet
need.
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